GALANTAMINE HYDROBROMIDE (galantamine hydrobromide) by Viatris (2) is alzheimer's disease (ad) is not fully understood, it has been reported that acetylcholine-producing neurons degenerate in the brains of patients with alzheimer's disease. Approved for mild to moderate dementia of the alzheimer's type, mild to moderate dementia of the alzheimer’s type (). First approved in 2009.
Drug data last refreshed 19h ago
Alzheimer's disease (AD) is not fully understood, it has been reported that acetylcholine-producing neurons degenerate in the brains of patients with Alzheimer's disease. The degree of this cholinergic loss has been correlated with degree of cognitive impairment and density of amyloid plaques (a…
Worked on GALANTAMINE HYDROBROMIDE at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease
Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study
A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia.